TY - JOUR
T1 - Persisting gastrointestinal symptoms and post-infectious irritable bowel syndrome following SARS-CoV-2 infection
T2 - Results from the Arizona CoVHORT
AU - Austhof, Erika
AU - Bell, Melanie L.
AU - Riddle, Mark S.
AU - Catalfamo, Collin
AU - McFadden, Caitlyn
AU - Cooper, Kerry
AU - Scallan Walter, Elaine
AU - Jacobs, Elizabeth
AU - Pogreba-Brown, Kristen
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Cambridge University Press.
PY - 2022/7/8
Y1 - 2022/7/8
N2 - In this study, we aimed to examine the association between gastrointestinal (GI) symptom presence during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the prevalence of GI symptoms and the development of post-infectious irritable bowel syndrome (PI-IBS). We used data from a prospective cohort and logistic regression to examine the association between GI symptom status during confirmed SARS-CoV-2 infection and prevalence of persistent GI symptoms at ≥45 days. We also report the incidence of PI-IBS following SARS-CoV-2 infection. Of the 1475 participants in this study, 33.8% (n = 499) had GI symptoms during acute infection. Cases with acute GI symptoms had an odds of persisting GI symptoms 4 times higher than cases without acute GI symptoms (odds ratio (OR) 4.29, 95% confidence interval (CI) 2.45-7.53); symptoms lasted on average 8 months following infection. Of those with persisting GI symptoms, 67% sought care for their symptoms and incident PI-IBS occurred in 3.0% (n = 15) of participants. Those with acute GI symptoms after SARS-CoV-2 infection are likely to have similar persistent symptoms 45 days and greater. These data indicate that attention to a potential increase in related healthcare needs is warranted.
AB - In this study, we aimed to examine the association between gastrointestinal (GI) symptom presence during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the prevalence of GI symptoms and the development of post-infectious irritable bowel syndrome (PI-IBS). We used data from a prospective cohort and logistic regression to examine the association between GI symptom status during confirmed SARS-CoV-2 infection and prevalence of persistent GI symptoms at ≥45 days. We also report the incidence of PI-IBS following SARS-CoV-2 infection. Of the 1475 participants in this study, 33.8% (n = 499) had GI symptoms during acute infection. Cases with acute GI symptoms had an odds of persisting GI symptoms 4 times higher than cases without acute GI symptoms (odds ratio (OR) 4.29, 95% confidence interval (CI) 2.45-7.53); symptoms lasted on average 8 months following infection. Of those with persisting GI symptoms, 67% sought care for their symptoms and incident PI-IBS occurred in 3.0% (n = 15) of participants. Those with acute GI symptoms after SARS-CoV-2 infection are likely to have similar persistent symptoms 45 days and greater. These data indicate that attention to a potential increase in related healthcare needs is warranted.
KW - COVID-19
KW - gastrointestinal
KW - post-acute sequelae of COVID-19
KW - post-infectious irritable bowel syndrome
UR - http://www.scopus.com/inward/record.url?scp=85133927714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133927714&partnerID=8YFLogxK
U2 - 10.1017/S0950268822001200
DO - 10.1017/S0950268822001200
M3 - Article
C2 - 35801302
AN - SCOPUS:85133927714
SN - 0950-2688
VL - 150
JO - Epidemiology and infection
JF - Epidemiology and infection
M1 - 2200120
ER -